Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodine 125-labeled monoclonal antibody A33
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iodine 125-labeled monoclonal antibody A33 is a radiolabeled murine IgG2a monoclonal antibody that targets the A33 antigen, a cell-surface glycoprotein expressed in over 95% of human colon carcinomas and normal colon epithelium. The drug is designed for radioimmunotherapy and diagnostic imaging in colorectal cancer. After binding to the target antigen on tumor cells, the radiolabeled antibody is internalized into cytoplasmic vesicles within the cell. The radioactive iodine-125 delivers localized radiation to tumor cells, resulting in cytotoxicity while sparing most normal tissues due to selective targeting. Clinical studies have shown specific localization and prolonged retention of the isotope at tumor sites with minimal toxicity at tested doses[1][4][5][6]. Developers: Memorial Sloan Kettering Cancer Center
- Other names
- radioiodinated monoclonal antibody A33I-125-A33I125-A33I 125-A33
02
Targets
GPA33 (Glycoprotein A33)
Beyond the preview
Go deeper on iodine 125-labeled monoclonal antibody A33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodine 125-labeled monoclonal antibody A33.